ATE516041T1 - Synergistische zusammensetzungen mit fk-228 - Google Patents

Synergistische zusammensetzungen mit fk-228

Info

Publication number: ATE516041T1
Authority: AT; Austria
Prior art keywords: antitumor agent; antitumor; synergistic compositions; agent; dna
Prior art date: 2004-02-25

Application number

AT05719967T

Other languages

English (en)

Inventor

Yoshinori Naoe

Takeshi Inoue

Yasuhiko Kano

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-25

Filing date

2005-02-25

Publication date

2011-07-15

2005-02-25 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE516041T1 publication Critical patent/ATE516041T1/de

Links

239000000203 mixture Substances 0.000 title 1
230000002195 synergetic effect Effects 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 abstract 6
230000000259 anti-tumor effect Effects 0.000 abstract 2
229940123237 Taxane Drugs 0.000 abstract 1
230000000340 anti-metabolite Effects 0.000 abstract 1
229940100197 antimetabolite Drugs 0.000 abstract 1
239000002256 antimetabolite Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Compositions Of Macromolecular Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT05719967T 2004-02-25 2005-02-25 Synergistische zusammensetzungen mit fk-228 ATE516041T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2004050520		2004-02-25
US56607704P	2004-04-29	2004-04-29
PCT/JP2005/003689 WO2005079827A2 (en)	2004-02-25	2005-02-25	Antitumor agent

Publications (1)

Publication Number	Publication Date
ATE516041T1 true ATE516041T1 (de)	2011-07-15

Family

ID=34889383

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05719967T ATE516041T1 (de)	2004-02-25	2005-02-25	Synergistische zusammensetzungen mit fk-228

Country Status (11)

Country	Link
US (2)	US7951780B2 (de)
EP (1)	EP1718322B1 (de)
JP (1)	JP4930055B2 (de)
AT (1)	ATE516041T1 (de)
CA (1)	CA2557540A1 (de)
CY (1)	CY1111926T1 (de)
DK (1)	DK1718322T3 (de)
PL (1)	PL1718322T3 (de)
PT (1)	PT1718322E (de)
SI (1)	SI1718322T1 (de)
WO (1)	WO2005079827A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1426054T3 (da) *	2001-08-21	2011-12-12	Astellas Pharma Inc	Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
US8673888B2 (en) *	2002-04-05	2014-03-18	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Depsipeptide for therapy of kidney cancer
EP1595952A4 (de) *	2003-02-19	2008-05-21	Astellas Pharma Inc	Verfahren zur abschätzung der antitumorwirkung des histondeacetylase-inhibitors
CA2540108A1 (en) *	2003-09-25	2005-04-07	Astellas Pharma Inc.	Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
US7951780B2 (en) *	2004-02-25	2011-05-31	Astellas Pharma Inc.	Antitumor agent
JP2009514889A (ja) *	2005-11-04	2009-04-09	メルクエンドカムパニーインコーポレーテッド	癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
EP1965824A4 (de) *	2005-11-18	2011-10-19	Gloucester Pharmaceuticals Inc	Metaboliten-derivate des hdac-inhibitors fk228
CA2649877A1 (en) *	2006-04-24	2007-12-21	Gloucester Pharmaceuticals	Gemcitabine combination therapy
WO2007146730A2 (en) *	2006-06-08	2007-12-21	Gloucester Pharmaceuticals	Deacetylase inhibitor therapy
EP2073837B1 (de) *	2006-10-06	2014-06-25	Bavarian Nordic Inc.	Rekombinanter modifizierter vaccinia ankara-virus zur kodierung eines her-2-antigens in kombination mit einem taxan zur verwendung in der krebsbehandlung
JP2010514801A (ja) *	2006-12-29	2010-05-06	グラスターファーマシューティカルズ，インコーポレイテッド	ロミデプシンの精製
CA2674313A1 (en) *	2006-12-29	2008-07-10	Gloucester Pharmaceuticals, Inc.	Romidepsin-based treatments for cancer
US9156792B2 (en) *	2008-05-09	2015-10-13	University Of Maryland, Baltimore	Retinamide and uses thereof
EP2366398A1 (de) *	2010-03-17	2011-09-21	Deutsches Krebsforschungszentrum	Krebstherapie mit einem Parvovirus in Kombination mit einem HDAC-Hemmer
MY166014A (en) *	2010-06-07	2018-05-21	Abraxis Bioscience Llc	Combination therapy methods for treating proliferative diseases
MX342913B (es)	2010-07-12	2016-10-19	Celgene Corp *	Formas solidas de romidepsina y sus usos.
US8859502B2 (en)	2010-09-13	2014-10-14	Celgene Corporation	Therapy for MLL-rearranged leukemia
AU2013202506B2 (en)	2012-09-07	2015-06-18	Celgene Corporation	Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en)	2012-11-14	2015-08-13	Celgene Corporation	Inhibition of drug resistant cancer cells
NZ630311A (en)	2013-12-27	2016-03-31	Celgene Corp	Romidepsin formulations and uses thereof
CN106860872B (zh) *	2017-01-18	2019-03-22	上海交通大学	用于逆转肿瘤对铂类抗癌药多药耐药性的两亲性药-药纳米颗粒药物及其制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8817743D0 (en) *	1988-07-26	1988-09-01	Fujisawa Pharmaceutical Co	Fr901228 substance & preparation thereof
JPH0315810A (ja) *	1989-06-13	1991-01-24	Minolta Camera Co Ltd	カメラ
WO1999022773A2 (en) *	1997-11-05	1999-05-14	Baylor College Of Medicine	Sequences for targeting metastatic cells
NZ518668A (en) *	1999-11-10	2004-04-30	Warner Lambert Co	Combination chemotherapy comprising acetyldinaline and paclitaxal and/or carboplatin
CA2393682C (en) *	1999-12-08	2012-01-31	Xcyte Therapies, Inc.	Depsipeptide and congeners thereof for use as immunosuppressants
ATE425177T1 (de)	2000-07-17	2009-03-15	Astellas Pharma Inc	Reduziertes fk228 und seine verwendung
JP2004508049A (ja)	2000-09-01	2004-03-18	藤沢薬品工業株式会社	Ｆｒ９０１２２８物質の製造法
WO2002049501A2 (en) *	2000-12-18	2002-06-27	Board Of Regents, University Of Texas System	Local regional chemotherapy and radiotherapy using in situ hydrogel
US6905669B2 (en) *	2001-04-24	2005-06-14	Supergen, Inc.	Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6620816B2 (en) *	2001-04-26	2003-09-16	Bristol-Myers Squibb Company	Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
DK1426054T3 (da)	2001-08-21	2011-12-12	Astellas Pharma Inc	Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
HUP0402341A3 (en) *	2001-08-31	2005-11-28	Bristol Myers Squibb Company P	Compositions containing thiazol-2-ylamines for the treatment of cancer
EP1293205A1 (de)	2001-09-18	2003-03-19	G2M Cancer Drugs AG	Valproinsäure und deren Derivate zur Kombinationsbehandlung von Krebs beim Menschen und zur Behandlung von Tumor-Metastasen und minimaler Resterkrankung
US8673888B2 (en) *	2002-04-05	2014-03-18	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Depsipeptide for therapy of kidney cancer
WO2003088954A1 (en)	2002-04-15	2003-10-30	Sloan-Kettering Institute For Cancer Research	Combination therapy for the treatment of cancer
PA8578001A1 (es) *	2002-08-07	2004-05-07	Warner Lambert Co	Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2004064727A2 (en)	2003-01-16	2004-08-05	Georgetown University	Method of cancer treatment using hdac inhibitors
EP1595952A4 (de)	2003-02-19	2008-05-21	Astellas Pharma Inc	Verfahren zur abschätzung der antitumorwirkung des histondeacetylase-inhibitors
DK2238982T3 (da) *	2003-06-27	2013-01-28	Astellas Pharma Inc	Terapeutisk middel til blødt væv-sarcom
CA2472842C (en)	2003-07-22	2012-05-29	Honda Motor Co., Ltd.	Working machine
CA2540108A1 (en) *	2003-09-25	2005-04-07	Astellas Pharma Inc.	Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
US20050187148A1 (en)	2004-02-25	2005-08-25	Yoshinori Naoe	Antitumor agent
US7951780B2 (en)	2004-02-25	2011-05-31	Astellas Pharma Inc.	Antitumor agent

2005
- 2005-02-24 US US11/064,292 patent/US7951780B2/en not_active Expired - Lifetime
- 2005-02-25 AT AT05719967T patent/ATE516041T1/de active
- 2005-02-25 CA CA002557540A patent/CA2557540A1/en not_active Abandoned
- 2005-02-25 JP JP2006526473A patent/JP4930055B2/ja not_active Expired - Lifetime
- 2005-02-25 EP EP05719967A patent/EP1718322B1/de not_active Expired - Lifetime
- 2005-02-25 PT PT05719967T patent/PT1718322E/pt unknown
- 2005-02-25 PL PL05719967T patent/PL1718322T3/pl unknown
- 2005-02-25 WO PCT/JP2005/003689 patent/WO2005079827A2/en not_active Ceased
- 2005-02-25 DK DK05719967.1T patent/DK1718322T3/da active
- 2005-02-25 SI SI200531350T patent/SI1718322T1/sl unknown
2011
- 2011-03-11 US US13/046,082 patent/US8822422B2/en active Active
- 2011-10-10 CY CY20111100965T patent/CY1111926T1/el unknown

Also Published As

Publication number	Publication date
US8822422B2 (en)	2014-09-02
WO2005079827A2 (en)	2005-09-01
DK1718322T3 (da)	2011-08-29
CY1111926T1 (el)	2015-11-04
EP1718322A2 (de)	2006-11-08
PT1718322E (pt)	2011-09-05
US20050187149A1 (en)	2005-08-25
PL1718322T3 (pl)	2011-12-30
EP1718322B1 (de)	2011-07-13
SI1718322T1 (sl)	2011-09-30
WO2005079827A3 (en)	2005-12-08
JP2007524650A (ja)	2007-08-30
US20110160295A1 (en)	2011-06-30
CA2557540A1 (en)	2005-09-01
JP4930055B2 (ja)	2012-05-09
US7951780B2 (en)	2011-05-31

Legal Events

Date

Code

Title

Description

2012-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1718322

Country of ref document: EP

Publication	Publication Date	Title
DK1718322T3 (da)	2011-08-29	Synergistiske sammensætninger med FK-228
MXPA06003222A (es)	2006-05-22	Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
EA200870019A1 (ru)	2008-12-30	Лактамовые соединения и способы их применения
WO2007103510A3 (en)	2007-12-13	Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
BRPI0807528A2 (pt)	2014-06-10	Composições lubrificantes pessoais complementares
MX2008010801A (es)	2008-09-05	Indolopiridinas como moduladores de quinesina eg5.
NO20073026L (no)	2007-08-27	2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
NO20082298L (no)	2008-07-17	Kaliumkanalinhibitorer
MY140514A (en)	2009-12-31	Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2007095258A3 (en)	2008-01-17	Rhamnolipid compositions and related methods of use
BRPI0722054A2 (pt)	2014-04-01	Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.
WO2007054573A3 (en)	2007-06-28	Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and egfr inhibitors or pyrimidine analogues
LTC2805723I2 (lt)	2022-04-25	Kladribino režimas, skirtas išsėtinei sklerozei gydyti
WO2009074677A3 (en)	2009-08-27	Pyrazolotriazines
GB2437149B (en)	2010-08-04	Synergistic preservative systems and their use in cosmetic compositions.
WO2009156182A3 (de)	2010-03-11	Uracilderivate und deren verwendung
WO2006061258A3 (en)	2006-09-28	Cytotoxic agents comprising new taxanes
IL178727A0 (en)	2007-02-11	Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same
AU2005273867A1 (en)	2006-02-23	Benzothienopyridines for use as inhibitors of Eg5 kinesin
EP2357003A4 (de)	2013-01-23	Zusammensetzung gegen krebs mit einem antitumorwirkstoff und einem stoff mit hemmender wirkung auf die l1cam-aktivität und -expression
DE602004014787D1 (de)	2008-08-14	Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
WO2009047434A3 (fr)	2009-08-13	Utilisation d'excipients en tant que conservateurs et composition pharmaceutique les comprenant
WO2007044325A3 (en)	2007-09-27	Apoe4 domain interaction inhibitors and methods of use thereof
ATE426409T1 (de)	2009-04-15	Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate
MY142792A (en)	2010-12-31	Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases